Characterization of Human CD4 T Cells Specific for a C-Peptide/C-Peptide Hybrid Insulin Peptide

Timothy A. Wiles1, Anita Hohenstein1,2, Laurie G. Landry3, Mylinh Dang1, Roger Powell1, Perrin Guyer4, Eddie A. James4, Maki Nakayama2,3, Kathryn Haskins2, Thomas Delong1 and Rocky L. Baker2*

1 Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, United States, 2 Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, United States, 3 Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, United States, 4 Department of Translational Research, Benaroya Research Institute at Virginia Mason, Seattle, WA, United States

Hybrid Insulin Peptides (HIPs), which consist of insulin fragments fused to other peptides from β-cell secretory granule proteins, are CD4 T cell autoantigens in type 1 diabetes (T1D). We have studied HIPs and HIP-reactive CD4 T cells extensively in the context of the non-obese diabetic (NOD) mouse model of autoimmune diabetes and have shown that CD4 T cells specific for HIPs are major contributors to disease pathogenesis. Additionally, in the human context, HIP-reactive CD4 T cells can be found in the islets and peripheral blood of T1D patients. Here, we performed an in-depth characterization of the CD4 T cell response to a C-peptide/C-peptide HIP (HIP11) in human T1D. We identified the TCR expressed by the previously-reported HIP11-reactive CD4 T cell clone E2, which was isolated from the peripheral blood of a T1D patient, and determined that it recognizes HIP11 in the context of HLA-DQ2. We also identified a HIP11-specific TCR directly in the islets of a T1D donor and demonstrated that this TCR recognizes a different minimal epitope of HIP11 presented by HLA-DQ8. We generated and tested an HLA-DQ2 tetramer loaded with HIP11 that will enable direct ex vivo interrogation of CD4 T cell responses to HIP11 in human patients and control subjects. Using mass spectrometric analysis, we confirmed that HIP11 is present in human islets. This work represents an important step in characterizing the role of CD4 T cell responses to HIPs in human T1D.

Keywords: CD4, hybrid insulin peptides, autoimmunity, mass spectrometry, type 1 diabetes, neoepitope, tetramer

INTRODUCTION

Type 1 diabetes (T1D) is an autoimmune disease driven by T cells specific for pancreatic β-cell autoantigens. Identifying β-cell antigens targeted by autoreactive T cells is an important step in understanding the etiopathogenesis of T1D. Post-translational modification of proteins can generate neo-epitopes in the periphery that are not represented in the thymus, providing a mechanism by which autoreactive T cells can evade central tolerance mechanisms and mediate β-cell destruction in the pancreatic islets. Hybrid Insulin Peptide (HIP) formation is a recently discovered modification that may
play a key role in the generation of primary targets of autoimmunity in T1D (1). HIPs are formed by covalent fusion of the N-terminus of β-cell secretory granule peptides (a right peptide) to the C-terminus of truncated insulin peptides (a left peptide) through a peptide bond. The resulting HIPs contain amino acid sequences not encoded by the genome, making them plausible targets for autoreactive T cells in T1D. We have identified HIPs in murine and human islets by mass spectrometry (1, 2), and a separate group recently demonstrated that HIPs can be found in the major histocompatibility complex (MHC) class II peptidome of mice (3).

In contrast to conventional post-translational modifications, such as phosphorylation or deamidation, which alter the side chain of a single amino acid residue, HIP formation leads to the replacement of an entire sequence of amino acids within insulin. This could have marked consequences for how a HIP, when compared to the unmodified precursor, binds to a given human leukocyte antigen (HLA) molecule and interacts with a specific T cell receptor (TCR). This, in turn, could result in recognition of a HIP in the periphery by T cells that did not recognize the corresponding unmodified peptides in the thymus during negative selection.

The role of HIPs as autoantigens in the non-obese diabetic (NOD) mouse model of T1D is clearly established. We have recently demonstrated that HIPs can be found in the major histocompatibility complex (MHC) class II peptidome of mice (3).

**HIP Nomenclature**

To avoid ambiguity and confusion, we developed a systematic nomenclature to describe the large diversity of potential HIP sequences. HIPs are identified using standard abbreviations for the proteins from which the left and right peptides originated (e.g., Ins, IAPP, CgA), separated by a dash. Next to each abbreviation, a subscript is used to describe the residues from the parent protein that span the sequence. For easy reference, insulin peptides are designated as “insA”, “insB”, or “insC”, indicating that the peptide originated from the A-chain, B-chain, or C-peptide region of insulin, respectively, and numbering is based on the position of the residues within the specific peptide. For peptides from all other proteins, residues are numbered based on their position in the pre-proprotein, with position 1 being the N-terminal residue of the signal peptide. For example, the HIP sequences DLQYGQVELGGPGA GSLQPLAL-EAE and SLQPLAL-EAEDLQV (hyphen indicates the HIP junction) referenced in this study are designated insC4-26 – insC1-3 and insC20-26 – insC1-7, respectively.

The defining feature of any individual HIP is its junction region. Trimming of a HIP – as may occur within an antigen-presenting cell, the proteasome, or with a protease used during sample preparation prior to LC-MS/MS analysis – could lead to the generation of peptides of different lengths that all represent the same HIP (i.e., they contain the same junction). Common names can be used to refer to a specific HIP junction. For example, the HIP generated when an insulin C-peptide fragment ending with residue 26 is fused to the N-terminus of C-peptide (insCx-26 – insC1-x) has been designated HIP11 (1). Both insC4-26 – insC1-3 and insC20-26 – insC1-7 are considered HIP11 peptides.

**Sequencing and Generation of E2a and E2b Transductants**

TCRα and TCRβ chain genes were amplified by 5’RACE-PCR, followed by sequencing on an MiSEQ sequencer (Illumina) as previously described (6). V- and J-gene usages as well as CDR3 sequences were then analyzed by IMGT/V-QUEST (http://www.imgt.org). The determined TCRα and TCRβ chain genes were expressed on a 5KC hybridoma cell line transduced with the NFAT-ZsGreen-1 reporter construct using a retroviral expression system as previously described (8).

Briefly, a murine stem cell virus-based retroviral vector encoding TCRα and TCRβ chain genes connected by a porcine-2A peptide was generated, and the reporter 5KC cell line was spinfected with a virus supernatant, genes connected by a porcine-2A peptide was generated, and the reporter 5KC cell line was spinfected with a virus supernatant, followed by MACS-based enrichment of transduced cells using magnetic beads conjugated with anti-CD3 antibody. The E2a and E2b transductants (2 x 10⁴ cells/well) were cultured with or without peptides along with K562 cells expressing DQ2 (DQA1*05:01-DQB1*02:01) or DR3 (DRA1*01:01-DRB1*03:01) at 5 x 10⁴ cells/well in a round-bottom 96 well plate overnight, followed by evaluating ZsGreen-1 expression by the TCR transductants on a Cytoflex flow-cytometer (Beckman Coulter).

**MATERIALS AND METHODS**

**Peptides**

The list of peptides used in this study were obtained commercially at >95% chromatographic purity and are listed in Supplementary Table 1.
were cultured with various concentrations of peptides in the presence of K562 cells expressing DQ8 (DQA1*03:01-DQB1*03:02) or DQ8trans (DQA1*05:01-DQB1*03:02) at 5 x 10^4 cells/well in a round-bottom 96 well plate overnight. ZsGreen-1 expression by the TCR transductants was analyzed on a Cytoflex flow-cytometer (Beckman Coulter).

**T Cell Clone Assays**

Early-passage CD4 T cell clones (E2, a HIP11-reactive clone and B11b, a HIP4-reactive clone) were thawed and restimulated with HIP11 or HIP4, respectively, in the presence of irradiated autologous EBV-transformed B-cell line as antigen-presenting cells (APC). Twenty-four hours later, IL-2 and IL-4 were added to the T cell cultures for T cell expansion. T cells were maintained in culture for 14-28 days before functional assays were performed. For T cell assays, CD4 T cell clones (0.5 – 5 x 10^5) were incubated either with the irradiated autologous EBV-transformed B-cell line (0.5 – 5 x 10^5 cells) or with irradiated PBMC from a partially HLA matched donor, in the presence or absence of antigen at indicated concentrations. For IFN-γ and TNF-α ELISA, supernatants were collected 24-48 hours after culture and analyzed using a kit from eBiosciences according to manufacturer’s protocol. To determine the DR- or DQ-HLA restriction of HIP responses, the antigen assay was performed in the presence and absence of anti-DR (L243) or anti-DQ (SPV-L3) antibodies. The EBV-transformed cell lines were first pulsed with peptide (50 µg/ml) and washed twice with AIM V medium. Antibodies were added at a final concentration of 1 µg/ml.

**Flow Cytometry**

For the CD25 upregulation assay, 1 x 10^5 CD4 T cells were cultured with an autologous EBV-transformed B cell line (1 x 10^5 cells) in the presence or absence of peptide. After 24 hours, cells were harvested, washed, and stained for CD4, CD25 and viability (eFluor780, Invitrogen) before analysis. Antibodies used for staining of T cells were anti-CD4 BV711 (SK3; BD Biosciences) and anti-CD25 BV421 (M-A251; BD Biosciences). Gating strategies are indicated in each figure: the lymphocyte gate was based on FSC/SSC properties and the singlets gate was based on the FSC-A/FSC-H. Samples were run on a BD Fortessa X-20 flow cytometer (5 lasers), a Cytak Aurora (5 lasers) or a CytoFlex (Beckton Dickinson) flow cytometer (3 lasers), and 5,000 – 50,000 cells were acquired for analysis. Data were analyzed using FlowJo v10 software (Tree Star, USA).

**Preparation of Islet Proteins**

Islets from a non-diabetic human donor (64 year-old male) were obtained from the University of Alberta Diabetes Institute Islet Core (Edmonton, Alberta, Canada). Upon arrival, islets were washed with phosphate-buffered saline (PBS) and then pelleted. The supernatant was removed and tubes were placed in liquid nitrogen to rapidly freeze the islet pellets. Islets were stored at -80°C until use. Islets were processed as described previously (2). Briefly, islets were thawed and lysed in 50% trifluoroethanol with heat and sonication, and cellular debris was pelleted by high-speed centrifugation. The supernatant, which contained extracted islet proteins, was fractionated by size exclusion chromatography (SEC). SEC fractions were then digested overnight at 37°C with the endoproteinase AspN (cleaves at the N-terminal side of aspartic acid residues) in buffer supplemented with zinc sulfate. Digested samples were dried in a vacuum concentrator and then reconstituted in loading buffer (2.7% acetonitrile/0.1% formic acid/water), sonicated, and spun at 17,000 x g for 2 minutes to remove any insoluble material. The supernatant was then analyzed by liquid chromatography tandem-mass spectrometry (LC-MS/MS).

**LC-MS/MS Analysis of Human Islet Proteins**

Samples were analyzed by LC-MS/MS using an Agilent 1200 series UHPLC system with a nanoflow adapter and an Agilent 6550 Q-TOF equipped with a nano-ESI source. Samples were separated online by reversed-phase liquid chromatography using a trap forward-elute configuration (trap column: Thermo Acclaim Pepmap 100, 75 µm x 2 cm, 3 µm particles, 100Å pores; analytical column: Thermo Acclaim Pepmap RSLC C18 analytical column, 75 µm inner diameter, 2 µm particles, 100Å pores). A water/acetonitrile gradient was used (buffer A: 0.1% formic acid in water; buffer B: 0.1% formic acid and 90% acetonitrile in water). Mass spectrometric data was collected in positive ion mode with an MS scan range of 290-1700 m/z, an MS acquisition rate of 5 spectra/sec, an MS/MS scan range of 50-1700 m/z, and a minimum MS/MS scan rate of 3 spectra/sec. Abundance dependent accumulation was enabled with a target of 80,000 counts/spectrum. Using auto-MS/MS mode, the ten most abundant precursors per cycle were selected for fragmentation (absolute threshold: 3000 counts; relative threshold: 0.01%). Singly-charged precursors were excluded.

**Analysis of Mass Spectrometric Data**

Data were searched using the Spectrum Mill MS Proteomics Workbench (Agilent, Rev B.06.00.201) and the SwissProt human proteome database. For data extraction, spectrum merging was enabled based on precursor selection purity, spectral similarity, retention time (2-minute window), and m/z. Search settings were as follows: instrument = Agilent ESI Q-TOF; precursor mass tolerance = +/- 10 ppm; product ion mass tolerance = +/- 20 ppm; digest = no enzyme. Matches were considered valid if the following thresholds were satisfied: score > 10, percentage scored peak intensity (SPI) > 70%, and rank 1 minus rank 2 (R1-R2) score > 2.5. Spectra that could not be confidently matched to unmodified peptides in the SwissProt database were subjected to a second round of searches using the settings listed above, except oxidized methionine and deamidated asparagine/glutamine were considered as variable modifications and digest was set to AspN (maximum of two missed cleavages). Spectra that remained unmatched according to the validation filters listed above were searched against a custom database containing hypothetical human HIPs (2) using the same settings as in the first search.

**Validation of HIP11 Identification Using Synthetic Peptide and the P-VIS Approach**

The HIP11 peptide-spectrum match (PSM) was first evaluated by applying our previously-published criteria (2). A synthetic version of the HIP11 peptide (GenScript, >95% pure) was then
used to validate the match by applying the novel PSM Validation with Internal Standards (P-VIS) approach recently developed by our group (9). In bottom-up proteomics, proteins from a biological spectrum are digested using a protease such as trypsin. The resultant peptides are analyzed by LC-MS/MS to generate fragmentation spectra. These spectra are then used to search a protein database, generating a large number of PSMs. Traditionally, to confirm that the correct sequence interpretation has been assigned to a particular fragmentation spectrum, the fragmentation spectrum of a synthetic version of the candidate sequence is compared to the fragmentation spectrum of the biological peptide in question using a metric such as the Pearson correlation coefficient. Since two spectra for the same peptide will not be entirely identical, the investigator decides subjectively if the similarity is high enough to indicate that the synthetic peptide and the biological peptide are the same. In the P-VIS approach (9), a set of internal standard peptides is spiked into both the biological sample and the synthetic peptide sample prior to LC-MS/MS analysis. For each internal standard peptide, the time of the biological peptide and synthetic peptide are close if the similarity is high enough to indicate that the synthetic peptide and the biological peptide are the same. In bottom-up proteomics, proteins from a biological sample and the synthetic peptide sample prior to LC-MS/MS analysis. For each internal standard peptide, the fragmentation spectra from the two samples are compared and the Pearson correlation coefficient is calculated. This information is used to determine a prediction interval for the Pearson correlation coefficient of a correct match. A similar process is used to determine if the chromatographic retention time of the biological peptide and synthetic peptide are close enough to indicate that the peptides are the same. PROCAL peptides (IPT Peptide Technologies) were used as internal standard peptides (10). LC-MS/MS analysis was performed as described above, except precursor selection was limited to those masses predicted for the peptides of interest. PSM_validator v1.4 (https://github.com/Delong-Lab/PSM_validator/releases) was used for data analysis with the following settings applied:

```
pre_mz_tol = 20, pro_mz_tol = 20, abund_thresh = 500, PCC_abund_thresh = 10, min_score = 30, min_weighted_score = 25, min_pairs_PCC = 8, min_PCC = 0.7, RTtol = 0.6, min_RT = 10, max_RT = 90, manual_RTdev_thresh = 0, min_intstd = 10, percentile_thresh = 5, ion_type = "b/y".
```

RESULTS

Response to HIP11 by the E2 CD4 T Cell Clone Is DQ2-Restricted

The HIP11-reactive CD4 T cell clone E2 was isolated from the peripheral blood of a patient with T1D (patient 3196) and in a previous study, we determined that the E2 response to HIP11 was restricted to HLA-DQ (6). We further confirmed these findings using thymidine incorporation as a read-out for T cell proliferation (Figure 1A). Since patient 3196 carries one copy of the DQ2 haplotype (DQA1*03:01-DQB1*02:01) and one copy of the DQA1*03:02-DQB1*03:03 haplotype, our goal was to determine the presenting HLA element. Using donor PBMCs partially matched for each haplotype as APCs, we tested the ability of the two haplotypes to stimulate the E2 CD4 T cell clone to HIP11. The E2 T cell clone proliferated when stimulated with the HIP11 peptide insC20-26 ~ insC17 (SLQPLAL–EAEDLQV) presented by PBMCs homozygous for DQ2, but not when presented by PBMCs homozygous for DQA1*03:02-DQB1*03:03 (Figure 1B). As an additional control, we determined that mis-matched PBMCs homozygous for DQ8 (DQA2*0301-DQB2*0302) did not stimulate the E2 T cell clone either at the 1 μM or the 10 μM concentration. To provide additional evidence of the presenting element, we used an artificial antigen-presenting line (K562) devoid of any HLA molecules and transduced with DQ2 or HLA-DRB1*03:01 (DR3) as a negative control (8). Each K562 line (expressing either DQ2 or DR3) was pulsed with the HIP11 peptide and cultured with the E2 T cell clone (Figure 1C). After 18h, upregulation of CD25 was assessed by flow cytometry as a measure of T cell activation. The E2 CD4 T cell clone upregulated CD25 in response to HIP11 only when the K562 line was transduced with DQ2, but not DR3, confirming our previous observation that the E2 T cell clone is stimulated by HIP11 in the context of DQ2.

Identification of TCR Responsible for Recognition of HIP11 by the E2 Clone

TCR sequencing of the E2 CD4 T cell clone revealed that two different TCRα chains – along with a single TCRβ chain – were expressed at the RNA level (6). It has been shown that dual TCRα-expressing T cells can contribute to autoimmunity through different processes, including escape of central tolerance (11) and failure to generate thymically-derived Tregs reactive to self-antigens (12). To determine which TCRα was responsible for the recognition of HIP11, each TCRα chain was expressed individually in combination with the cognate TCRβ chain in a TCR-deficient hybridoma (5KC) engineered with a ZsGreen-1 fluorescent protein gene, under the NFAT promoter (8). Under these conditions, the TCR transductants express ZsGreen-1 when the TCR is engaged with the peptide-MHC complex, enabling monitoring of T cell activation by flow cytometry. The resulting transductants, E2a and E2b (expressing either TRAV6 or TRAV8-2/8-4 respectively), were then challenged with HIP11-pulsed artificial APCs (K562 line expressing DQ2). The E2b – but not the E2a – transdant recognized HIP11 in the context of DQ2 (Figure 1D), demonstrating that the combination of the TRAV8-2/8-4 TCRα chain with the TRBV5-4 TCRβ chain is responsible for recognizing HIP11.

Characterization of a HIP11-Specific TCR From the Islets of a T1D Donor

We previously isolated T cell clones and lines from the residual islets of human T1D donors recognizing four different HIPs containing a sequence from the C-peptide linked to insulin A-chain, Islet Amyloid Poly peptide, or Neuropeptide Y (1, 5). Although the E2 clone, which was isolated from the peripheral blood of a T1D patient, is specific for HIP11, isolating a HIP11-reactive T cell clone from the islets – the actual site of autoimmune destruction – would further establish the relevance of HIP11 as an autoantigen in human T1D. Michels et al. previously generated transductants expressing TCRs identified by direct TCR sequencing of islet-infiltrating T cells.
in organ donors with T1D (13). Several of the CD4 T cell transductants were shown to be reactive to proinsulin peptides. The CD4 T cell transductant GSE.8E3 responded to the peptide insC17-33 (GAGSLQPLALEGSLQKR), a region of the C-peptide prone to HIP formation (2). We previously tested reactivity of human PBMCs to eight HIPs containing that region of the C-peptide (6) and found that reactivity to two of them (HIP11 and HIP16) was increased (compared to no antigen) in T1D patients but not in control subjects (6). We hypothesized that post-translational modification of the C-peptide fragment through hybrid peptide formation would generate a more potent antigen for GSE.8E3. Eight HIPs containing the insulin C-peptide fragment insC20-26 as the left peptide were tested for antigenicity. The GSE.8E3 transductant strongly reacted to the HIP11 peptide insC20-26 – insC1-7 (SLQPLAL–EAEDLQV) in the context of both DQ8 and DQ8trans (Figure 2). When DQ8 was the presenting element, GSE.8E3 did not respond to the native insulin peptide insC16-31 (PGAGSLQPLALEGSLQ) (Figure 3A) except at very high concentrations (Figure 2). GSE.8E3 did respond to insC16-31 when presented by DQ8-trans (Figure 3B). The E2 clone did not respond to native C-peptide when presented by DQ2 (Figure 3C).

**E2 and GSE.8E3 Recognize Different Minimal Epitopes of HIP11**

Although the E2 and GSE.8E3 TCRs both recognized HIP11, it was possible that they were specific for different HIP11 epitopes, particularly since recognition by these TCRs was restricted to different HLA molecules. Identifying the precise epitope recognized by each TCR could facilitate future efforts to characterize the immune response to HIP11. For example, it could enable the generation of HLA class II tetramers that allow for detection of different subsets of HIP11-reactive T cells in human subjects. To determine the minimal epitope recognized by the E2 T cell clone and the islet-derived GSE.8E3 transductant, we tested reactivity to HIP11 peptides truncated...
either on the N- or the C-terminus. Our data show that the response by the E2 T cell clone was completely abrogated when the glutamine on the N-terminus was missing (Figure 4A) and when the aspartic acid (D) on the C-terminal region was truncated (Figure 4B), indicating that the minimal HIP11 epitope seen by the E2 T cell clone is QPLALEAE. For the GSE.8E3 transductant, our data show that the minimal epitope presented by DQ8 is LQPLALEAE (Figures 4A, B). Results were similar when testing the GSE.8E3 response using DQ8trans as the presenting element (Supplementary Figure 1). Residues flanking these minimal epitopes also seem to contribute to overall activity, possibly as TCR contact residues outside of the peptide binding groove. Based on these data and published data regarding preferred binding residues for DQ2 and DQ8 (14, 15), we propose that HIP11 is presented in two different binding registers depending on whether DQ2 or DQ8 is the presenting element, as shown in Figure 4C.

**Design and Validation of an HLA-DQ2/ HIP11 Tetramer**

The study of antigen-specific T cells is a high priority in T1D research as CD4 T cells reactive to islet antigens could potentially serve as biomarkers of disease progression in at-risk subjects. While ELISpot analysis can detect cytokine-secreting cells independent of MHC restriction, HLA class II tetramers allow for the detection, enumeration, and phenotyping of antigen-specific T cells directly ex vivo (16). Based on the discovery that the response of the HIP11-reactive CD4 T cell clone E2 to HIP11 was DQ2-restricted, we designed an HLA class II tetramer loaded with the HIP11 peptide and tested its ability to stain the E2 T cell clone. As a negative control we used the T cell clone B11b, which is reactive to HIP4, a C-peptide/A-chain hybrid peptide (Supplementary Figure 2). While the HIP11-reactive T cell clone stained with the DQ2/HIP11 tetramer, the HIP4-reactive T cell clone B11b did not (Figure 5A). Neither of the CD4 T cell clones stained with a negative control DQ2 tetramer loaded with the CLIP peptide (Figure 5A). To determine whether antigen stimulation of the T cell clone could improve tetramer binding, the E2 and B11b T cell clones were stimulated with HIP11 or HIP4 respectively in the presence of autologous EBV-transformed PBMCs. T cells were stained with either the HIP11 or the CLIP tetramers 8, 12 and 23 days after stimulation and tetramer staining was monitored by flow cytometry (Figure 5A). Our data indicate that the strongest staining is obtained within a week after stimulation. Finally, PBMCs from two DQ2+ T1D patients (with T1D onset less that 2 years) were cultured with medium only or in the presence of HIP4 or HIP11. After 10 days of culture, cells were harvested and stained with the HIP11 tetramer. A substantial population of CD4 T cells present in one of the patients stained with the HIP11/DQ2 tetramer when PBMCs were stimulated with HIP11, but not when stimulated with an irrelevant HIP (Figure 5B).

**HIP11 Is Present in Human Islets**

A critical step in confirming that HIP11 is a natural antigen in human T1D was to identify HIP11 in human islets by mass spectrometry (LC-MS/MS). Proteins were isolated from non-diabetic human donor islets and digested with the protease AspN to generate peptides suitable for mass spectrometric analysis. Resultant
**FIGURE 4** | The E2 CD4 T cell clone and the GSE.8E3 TCR transductant recognize different minimal epitopes. N-terminally (A) and C-terminally (B) truncated HIP11 peptides were tested with E2 and GSE.8E3 for antigenicity. Results are representative of three independent experiments. (C) Proposed binding registers for HIP11 in the context of DQ2 or DQ8 when recognized by E2 or GSE.8E3, respectively.

**FIGURE 5** | HIP11/DQ2 tetramer stains the E2 T cell clone and PBMCs from a T1D patient. (A) The E2 or B11b T cell clones were stimulated with HIP11 or HIP4 respectively and an irradiated autologous EBV-transformed B cell line. T cells were then maintained in culture and harvested at 8, 12 and 23 days post-stimulation and stained with the DQ2/HIP11 tetramer (blue histograms) or DQ2/CLIP tetramer (red histograms), CD4, and a fixable viability dye. Tetramer staining was assessed by flow cytometry by gating on live, CD4+ cells. Data are representative of two independent experiments. (B) PBMCs from two DQ2+ patients were isolated, stained with CFSE and cultured with medium only, HIP4, or HIP11. After 10 days, cells were harvested and stained with the DQ2/HIP11 tetramer, anti-CD4 and anti-CD25 antibodies, and a fixable viability dye before flow cytometry analysis. Gates were set on live, CD4+ CD25+ CFSElow events and the percentage of tetramer positive events is reported.
peptides were then analyzed by LC-MS/MS, and data were searched against a custom database to find peptides describing the HIP11 hybrid junction. Our analysis identified the peptide insC4-26 – insC1-3 (DLQVGQVELGGPGAGSLQPLAL-EAE) with high confidence (Figure 6A and Supplementary Table 2). This peptide is the predicted AspN cleavage product of HIP11. We previously established a set of rigorous criteria to confidently identify HIPs by mass spectrometry (2), and the putative HIP11 match satisfied all of these criteria (Supplementary Table 3). To further confirm the validity of the mass spectrometry-based HIP11 identification, we applied a novel approach – Peptide-spectrum match Validation with Internal Standards (P-VIS) – recently developed by our group (9). Using this approach, the fragmentation spectrum of the peptide found in human islets was found to be highly similar to the spectrum of synthetic insC4-26 – insC1-3 peptide (Figure 6A), with a Pearson correlation coefficient of 0.953 (Figure 6B). Based on the data for internal standard peptides, this degree of correlation indicated that the peptide found in human islets was indeed the HIP11 peptide insC4-26 – insC1-3 (Figure 6C). This finding was confirmed by P-VIS chromatographic retention time analysis (Supplementary Figure 3).

**DISCUSSION**

The discovery of HIPs in human islets (2) and the detection and isolation of HIP-reactive CD4 T cells from the peripheral blood and islets of individuals with T1D (1, 5–7) indicate a role for HIPs as autoantigens in T1D. Here, we used LC-MS/MS analysis
to report for the first time that HIP11, a C-peptide/C-peptide HIP, is present in human islets. We determined the TCR Vα and VB usage and the HLA class II restriction of the HIP11-reactive E2 clone previously isolated from the peripheral blood of a T1D donor. We also demonstrated that HIP11 is a potent epitope for a proinsulin-specific T cell receptor (GSE.8E3) identified by analysis of islet-infiltrating T cells from a T1D organ donor (13). Notably, we found that GSE.8E3 and the E2 clone each recognize a different minimal epitope of HIP11 and recognition by these clones was restricted to HLA-DQ8/HLA-DQ8\textsuperscript{trans} or HLA-DQ2, respectively. HLA-DQ8 and HLA-DQ8\textsuperscript{trans} consist of the same β chain paired with different α chains. A previous study (17) demonstrated that CD4 T cell clones (isolated from T1D donors and specific for immunodominant islet epitopes) could recognize their cognate peptide epitopes presented by either DQ8 or DQ8\textsuperscript{trans}, with presentation by DQ8\textsuperscript{trans} eliciting a stronger response. The DQ8\textsuperscript{trans} α chain lacks the Arg52 residue present in the DQ8 α chain. The authors demonstrated that the absence of Arg52 led to differences in the orientation of TCR contact residues in the bound peptide, resulting in a higher affinity between the TCR and the peptide-DQ8\textsuperscript{trans} complex (17). The GSE.8E3 transfectoma was more sensitive to N-terminal and C-terminal truncations of the HIP11 peptide SLQPLAL-EAEDLQV when DQ8 was the presenting element, also suggesting possible differences in the orientation of crucial TCR contacts when either DQ8 or DQ8\textsuperscript{trans} was the presenting element. However, structural characterization, such as by X-ray crystallography, would be needed for definitive characterization of the interactions between the TCR, the peptide, and the different HLA molecules.

As more than 73% of all patients with T1D carry either HLA-DQ8 (DQA2*0301-DQB2*0302), HLA-DQ2 (DQA1*0501-DQB1*0201), or both (18), presentation by two different HLA DQ8 (DQA2*0301-DQB2*0302), HLA-DQ2 (DQA1*0501-DQB1*0201), or both (18), presentation by two different HLA

HIPs that do not form in the thymus. Thus, central tolerance to HIPs that do not form in the thymus.

formation of a cis-hybrid? In this scenario, a protease would cleave of this cyclic peptide by a protease or the proteasome could then generate a linear HIP11 peptide suitable for presentation by MHC molecules. Alternatively, HIP11 could be formed by intermolecular transpeptidation (formation of a trans-hybrid), in which one C-peptide molecule is cleaved, generating the insulin peptide to an biological peptide since human islet proteins were digested with the AspN protease prior to LC-MS/MS analysis. Could HIP11 be the product of intramolecular transpeptidation and therefore the generation of a cis-hybrid? In this scenario, a protease would remove the five C-terminal residues from a C-peptide molecule and fuse the N-terminus of the same molecule to the newly-formed C-terminus, thereby generating a cyclic peptide. Cleavage of this cyclic peptide by a protease or the proteasome complex could then generate a linear HIP11 peptide suitable for presentation by MHC molecules. Alternatively, HIP11 could be formed by intermolecular transpeptidation (formation of a trans-hybrid), in which one C-peptide molecule is cleaved, generating the fragment, and the N-terminus of a separate C-peptide molecule is fused to the C-terminus of the insC\textsubscript{1-26} fragment. Various other details of how HIP11 is formed are also unknown including for example, the specific enzyme responsible for formation of HIP11 in human islets.

In combination with our previous work, our results provide a thorough analysis of a disease-relevant HIP in human T1D, including identification of the HIP in islets, investigation of CD4 T cell responses, and molecular characterization of epitope recognition. The validation of an HLA-DQ2/HIP11 tetramer opens the path for further characterization of the role of HIP11-reactive T cells in T1D. To our knowledge, this is one of the first DQ2 tetramers loaded with a T1D disease-relevant antigen. This work provides a precedent for in-depth characterization of peptides, potentially resulting in a more robust autoimmune response. We observed, for example, that the GSE.8E3 transductant, which responded to HIP11 in the context of either HLA-DQ8 or HLA-DQ8\textsuperscript{trans}, also responded to native C-peptide but only when presented by DQ8\textsuperscript{trans} and not by DQ8. One could speculate that the ability of HLA-DQ8\textsuperscript{trans} to present both a HIP and an unmodified insulin peptide to an autoreactive T cell clone in a stimulatory fashion suggests a possible mechanism in which carrying both the HLA-DQ2 and HLA-DQ8 alleles increases the risk of developing T1D by facilitating T cell cross reactivity to HIPs and unmodified peptides. It should be noted that HIP11 could be found in the islets of a non-T1D organ donor, suggesting that HIP formation is not limited to humans with autoimmunity. Similarly, insulin has long been recognized as an autoantigen in T1D, even though it is expressed in all individuals. Elucidating how various factors such as HIP formation and HLA genotype act in concert to promote disease development could be key to future progress in T1D research.
responses to HIPs as important components of the autoimmune response in T1D.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. The data presented in the study are included in the article figures, tables, and supplementary materials. The T cell receptor alpha and beta chain sequences and corresponding epitope data were submitted to the immune epitope database (https://www.immuneepitope.org) and can be accessed as submission ID 1000868. Further inquiries about the data can be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Colorado Multiple Institutional Review Board. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

**AUTHOR CONTRIBUTIONS**

RB, TW, MN, and EJ designed experimental work. AH, RB, TW, MD, LL, RP, and MN performed experimental work. RB, TW, KH, and TD wrote and edited the manuscript. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Delong T, Wiles TA, Baker RL, Bradley B, Barbour G, Reisendorf R, et al. Pathogenic CD4 T Cells in Type 1 Diabetes Recognize Epitopes Formed by Peptide Fusion. Science (80-. ). (2016) 351:711–4. doi: 10.1126/science.aad2791
2. Wiles TA, Powell R, Michel CR, Scott Beard K, Hohenstein A, Bradley B, et al. Identification of Hybrid Insulin Peptides (HIPs) in Mouse and Human Islets by Mass Spectrometry. J Proteome Res (2019) 18:814–25. doi: 10.1021/acs.jproteome.8b00875
3. Wan X, Vomund AN, Peterson OJ, Cherovensky AV, Lichti CF, Unanue ER. The MHC-II Peptidome of Pancreatic Islets Identifies Key Features of Autoimmune Peptides. Nat Immunol (2020) 21:455–63. doi: 10.1038/s41590-020-0623-7
4. Baker RL, Jamison BL, Wiles TA, Lindsay RS, Barbour G, Bradley B, et al. CD4 T Cells Reactive to Hybrid Insulin Peptides Are Indicators of Disease Activity in the NOD Mouse. Diabetes (2018) 67:1836–46. doi: 10.2337/db18-0200
5. Babon JAB, DeNicola ME, Blodgett DM, Crèvecoeur I, Buttrick TS, Maehr R, et al. Analysis of Self-Antigen Specificity of Islet-Infiltrating T Cells From Human Donors With Type 1 Diabetes. Nat Med (2016) 22:1482–7. doi: 10.1038/nm.4203
6. Baker RL, Rihanek M, Hohenstein AC, Nakayama M, Michels A, Gottlieb PA, et al. Hybrid Insulin Peptides Are Autoantigens in Type 1 Diabetes. Diabetes (2019) 68:1830–40. doi: 10.2337/db19-0128
7. Arribas-Layton D, Guyer P, Delong T, Dang M, Chow IT, Speake C, et al. Hybrid Insulin Peptides Are Recognized by Human T Cells in the Context of Drb1*0401. Diabetes (2020) 69:1492–502. doi: 10.2337/db19-0162
8. Mann SE, Zhou Z, Landry LG, Anderson AM, Alkanani AK, Fischer J, et al. Multiplex T Cell Stimulation Assay Utilizing a T Cell Activation Reporter-Based Detection System. Front Immunol (2020) 11. doi: 10.3389/fimmu.2020.00633
9. Wiles TA, Saba LM, Delong T, Peptide–Spectrum Match Validation With Internal Standards (P–VIS): Internally-Controlled Validation of Mass Spectrometry-Based Peptide Identiﬁcations. J Proteome Res (2020) 20 (1):236–49. doi: 10.1021/acs.jproteome.0c00355
10. Zolg DP, Wilhelm M, Yu P, Knaute T, Zerweck J, Wenschuh H, et al. PROCAL: A Set of 40 Peptide Standards for Retention Time Indexing, Column Performance Monitoring, and Collision Energy Calibration. Proteomics (2017) 17. doi: 10.1002/pmc.201700263
11. Ji Q, Perchellt A, Governan JM. Viral Infection Triggers Central Nervous System Autoimmunity Via Activation of CD8 + T Cells Expressing Dual TCRs. Nat Immunol (2010) 11:628–34. doi: 10.1038/ni.1888
12. Schuld NF, Auger JL, Spanier JA, Martinov T, Breed ER, Fife BT, et al. Cutting Edge: Dual TCR Expression Poses an Autoimmune Hazard by Limiting Regulatory T Cell Generation. J Immunol (2017) 199:33–8. doi: 10.4049/jimmunol.1700406
13. Michels AW, Landry LG, McDaniel KA, Yu L, Campbell-Thompson M, Kwok WW, et al. Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes. Diabetes (2017) 66:722–34. doi: 10.2337/db16-1025
14. Vartdal F, Johansen BH, Friede T, Thorpe CJ, Stevanovic S, Eriksen JE, et al. The Peptide Binding Motif of the Disease Associated HLA-DQ (α 1(*) 0501, β 1(*) 0201) Molecule. Eur J Immunol (1998) 26:2764–72. doi: 10.1002/eji.180261132
15. Chang KY, Unanue ER. Prediction of HLA-DQ8 Cell Peptide Identiﬁcations. J Immunol (2009) 21:705–13. doi: 10.1039/immunol/dx0309
16. Nepom GT. MHC Class II Tetramers. J Immunol (2012) 188:2477–82. doi: 10.4049/jimmunol.1102398
17. Chow IT, Gates TJ, Papadopoulos GK, Moustakas AK, Kolaowiec EM, Notturno RJ, et al. Discriminative T Cell Recognition of Cross-Reactive Islet-Antigens Is Associated With HLA-DQ8 Transdimer–Mediated Autoimmune Diabetes. Sci Adv (2019) 5:eava9936. doi: 10.1126/sciadv.aav936
18. Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Connannon P, et al. HLA DR-DQ Haplotypes and Genotypes and Type 1 Diabetes Risk Analysis of the Type 1 Diabetes Genetics Consortium Families. Diabetes (2008) 57:1084–92. doi: 10.2337/db07-1331

**FUNDING**

This study was supported by the American Diabetes Association (ADA) Pathway to Stop Diabetes 1-15-ACE-14 (TD), National Institutes of Health (NIH) research grants R21AI133059 (RB), R01 AI146202-01A1 (RB), R01DK081166 (KH), R01DK119529-02 (TD), R01DK099317 (MN), R01DK30283 (MN), Juvenile Diabetes Research Foundation grants 2-SRA-2016-226-S-B (TD), 1-SRA-2020-911-A-N (MN), and PDF-2019-746-A-N (TW).

**ACKNOWLEDGMENTS**

We would like to thank the NIH tetramer core for providing the tetramers used in this study, Dr. Peter Gottlieb for providing patients samples and James Dilisio for assistance with flow cytometry experiments.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.668680/full#supplementary-material
19. Pociot F, McDermott MF. Genetics of Type 1 Diabetes Mellitus. *Genes Immun* (2002) 3:235–49. doi: 10.1038/sj.gene.6363875

20. Jones EY, Fugger L, Strominger JL, Siebold C. MHC Class II Proteins and Disease: A Structural Perspective. *Nat Rev Immunol* (2006) 6:271–82. doi: 10.1038/nri1805

21. Van De Wal Y, Kooy YMC, Drijfhout JW, Amons R, Koning F. Peptide Binding Characteristics of the Coeliac Disease Associated DQ(a1(*)0501, b1(*) 0201) Molecule. *Immunogenetics* (1996) 44:246–53. doi: 10.1007/BF02602553

22. Van Lummel M, Van Veelen PA, De Ru AH, Pool J, Nikolic T, Laban S, et al. Discovery of a Selective Islet Peptidome Presented by the Highest-Risk HLA-DQ8trans Molecule. *Diabetes* (2016) 65:732–41. doi: 10.2337/db15-1031

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Wiles, Hohenstein, Landry, Dang, Powell, Guyer, James, Nakayama, Haskins, Delong and Baker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.